ArticleCancer discovery2019
Tissue-Specific Oncogenic Activity of KRAS
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.
- Cancer in Multilineage Mosaic RASopathies due to Pathogenic Variants in HRAS or KRAS: A Systematic Review and Meta-analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Blood advances · 2026Article
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Why are Some Tissues More Vulnerable? Revisiting Tissue Specificity in Hereditary Cancer Syndromes.Molecular diagnosis & therapy · 2026Review
- Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response.Nature genetics · 2026Article
- Diverse roles of SERPINE1 in regulating cellular proliferation and invasion.International journal of oncology · 2026Article
- The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium.Oncogene · 2026Article
- A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient population.medRxiv : the preprint server for health sciences · 2026Article
- PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.Cancer research · 2026Article
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- Lineage plasticity: a new dilemma in lung cancer treatment.Molecular biology reports · 2026Review
- Prognostic Implications of Codon-SpecificJCO precision oncology · 2026Article
- Generation of Human Haematopoietic Model Cell Lines Revealed Distinct Replication Stress Tolerance Between Two OncogenicBiomolecules · 2026Article
- Interpreting the functional impact of genetic variants: The need for context qualifiers.American journal of human genetics · 2026Review
- Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.bioRxiv : the preprint server for biology · 2026Article
- Measuring and locating the changes in protein structure using MELO.Nature communications · 2026Article
- KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.NPJ precision oncology · 2025Article
- Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Differential effects of KRAS G-domain and hypervariable region mutants on cancer phenotypes.Scientific reports · 2025Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 8 institutions in 2 countries.
Emily J PoulinCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0001-6428-5963
Asim K Bera *Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Jia Lu *Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Yi-Jang LinCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Samantha Dale StrasserCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4291-413X
Tannie Q HuangDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Carolina MoralesDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Wei YanDepartments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Joshua CookCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0001-9815-6879
Jonathan A NowakDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Douglas K BrubakerCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Brian A JoughinKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0003-1022-9450
Christian W JohnsonCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Rebecca A DeStefanisCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Phaedra C GhaziCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0002-0884-9442
Sudershan GondiDepartments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Thomas E WalesDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts.
Roxana E IacobDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts.
Lana BogdanovaDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Jessica J GierutCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Yina LiCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
John R EngenDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts.ORCID 0000-0002-6918-9476
Pedro A Perez-ManceraDepartment of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Benjamin S BraunDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Kenneth D WestoverDepartments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas. khaigis@bidmc.harvard.edu Kenneth.Westover@UTSouthwestern.edu.ORCID 0000-0003-3653-5923
Kevin M HaigisCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts. khaigis@bidmc.harvard.edu Kenneth.Westover@UTSouthwestern.edu.ORCID 0000-0003-1922-4509
Beth Israel Deaconess Medical Center · USThe University of Texas Southwestern Medical Center · USUCSF Helen Diller Family Comprehensive Cancer Center · USNortheastern University · USHarvard University · USMassachusetts Institute of Technology · USBrigham and Women's Hospital · USUniversity of Liverpool · GB
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MSystems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacyU01CA215798 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HAAS, WILHELM, HAIGIS, KEVIN · 2017 to 2021
$3.7MBasic and Translational studies of Ras-mutant colorectal cancerR01CA178017 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HAIGIS, KEVIN · 2014 to 2018
$1.8MModeling KRAS genetic heterogeneity in mouse modelsR01CA195744 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HAIGIS, KEVIN · 2016 to 2018
$1.7MMechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasiaR01CA173085 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRAUN, BENJAMIN · 2013 to 2017
$1.6MResolving the role of nicotine-mediated phosphorylation on pancreatic fibrosisK01DK098285 · NIDDK · HARVARD MEDICAL SCHOOL · PI PAULO, JOAO A · 2013 to 2017
$638kCancer Research UK 27144Cancer Research UK C5470/A27144NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA173085NCI NIH HHS R01 CA178017NCI NIH HHS R01 CA195744NCI NIH HHS T32 CA128583NCI NIH HHS U01 CA215798NIDDK NIH HHS K01 DK098285
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllelesMutationOncogenesCell Transformation, NeoplasticHumansModels, MolecularNeoplasmsOrgan SpecificityPhenotypeProtein ConformationProteomeProteomicsProto-Oncogene Proteins p21(ras)Structure-Activity RelationshipKRAS protein, humanProteomeProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.